Pilgrim's Pride, Exelixis, Synchrony and United Airlines have been highlighted in this Screen of The Week article.

Evaluate the expected performance of Exelixis (EXEL) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key ...

Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...

The genomics industry is set for growth due to advancements in personalized medicine, diagnostics, and biotech innovations.

Wall Street expects a year-over-year increase in earnings on higher revenues when Alnylam Pharmaceuticals (ALNY) reports results for the quarter ended December 2024. While this widely-known consensus ...

The equity market in 2025 so far has been characterized by heightened volatility, primarily driven by escalating geopolitical tensions and renewed trade conflicts. Trump's aggressive tariff policies ...

Researchers observed improvements in rates of burnout and work-life integration challenges among a cohort of U.S. medical oncology fellows in 2023 vs. 2013, but challenges remain, according to survey ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued stocks in the Pharmaceuticals industry for Thursday, February 06, 2025. Let’s ...